For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Ye, after a weekend of spewing more antisemitic and hateful comments on X, offered a message of praise for the app’s owner, Elon Musk. “I appreciate Elon for allowing me to vent,” the ...

Vertex Pharmaceuticals Inc (VRTX) reports robust financial performance with significant revenue growth and strategic product launches, despite facing international IP challenges. Biotech company ...

Vertex' portfolio has been steadily expanded with new product launches to cover the majority of CF mutations, and so it has been looking at new therapeutic categories – including T1D ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.